Scott B. Kozak has over 30 years of experience in the pharmaceutical/life science industry and has held senior positions in marketing, brand management, business development, licensing & corporate development. He is currently the Vice President, Research Business Development at the Muscular Dystrophy Association (MDA).

Kozak has helped several companies partner assets, raise funds, and create exits. Most recently, Kozak was the Chief Business Development Officer for AI therapeutics, a CT-based company focused on the development of Rare & Orphan Disease therapeutics. Just prior, he was the Head of Business Development for Universal Sequencing Technology (UST), a next-generation DNA Sequencing company located in Boston, spearheading a major partnership with the world’s largest DNA sequencing company. Additionally, Kozak was an Entrepreneur-In-Residence & Head of Licensing & Business Development for AlloMek, a recently acquired New Haven, CT-based Rare Disease & Oncology company, founded by an ex-Bayer scientist & backed by the CT-based venture capital group Connecticut Innovations. Kozak has also worked with the UConn Incubator company, Potentiometric Probes, a company that is marketing Voltage-Sensitive Dyes for cardiovascular & neurological drug discovery, to help them raise funds and find global distribution partners.